Loading
Latest filing published 13 Sept 2022 for Navidea Biopharmaceuticals, INC.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Michael Stanley Rosol, listed as senior executive, appears in our data through filings on Navidea Biopharmaceuticals, Inc. shares, published by SEC (Form 4). We count 2 filings; the first trade dates from 14 January 2022 and the latest from 9 September 2022.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
The record was last updated on 13 September 2022 with a share grant in Navidea Biopharmaceuticals, Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 of 2 declarations